knowledge -WSS

knowledge

author：knowledge 2025-09-30 00:34:21 - browse：44

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

WSS

Bright Health sells Medicare Advantage business to Molina

WHO calls for emergency meeting on new China virus, as cases spread

BioMarin wins approval for gene therapy to treat hemophilia A

How Medicaid coverage policies for immigrants impact new moms

Tori Bowie and the unacceptable rates of Black maternal death

How Medicaid coverage policies for immigrants impact new moms

hotspot

knowledge

knowledge

Activists slam private health insurers over coverage restrictions

Novavax promises a turnaround & Lilly roils the obesity market

State Dept. review finds Biden bears some blame for Afghanistan failures

As digital health tech proliferates, a new institute aims to cut through hype

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Jerome Adams on the need for new antivirals for Covid

How dance can help nurses traumatized by Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How one medical school became remarkably diverse

leisure time

Google and Epic fight stronger regulation of AI in health care

Wildfire smoke exposes gaps in outdoor worker protections

How one medical school became remarkably diverse

23andMe had bad news about my health. I wish a person had delivered it

BioMarin wins approval for gene therapy to treat hemophilia A

Affirmative action in medical school literally saved lives

leisure time

focus

hotspot

hotspot